Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Finding the maximum safe dose level for heteroscedastic data.

Ajit C Tamhane1, Brent R Logan

  • 1Departments of IE/MS and of Statistics, Northwestern University, Evanston, IL 60208, USA. ajit@iems.northwestern-edu

Journal of Biopharmaceutical Statistics
|December 14, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Blood advances·2026
Same author

TITE-safety: a robust time-to-event safety monitoring approach for clinical trials.

Biometrics·2026
Same author

Hematopoietic Cell Transplant Access and Patient Diversity.

JAMA network open·2026
Same author

Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study.

bioRxiv : the preprint server for biology·2026
Same author

The BIOPREVENT machine-learning algorithm predicts chronic graft-versus-host disease and mortality risk using posttransplant biomarkers.

The Journal of clinical investigation·2026
Same author

Neurodevelopmental outcomes following hematopoietic cell transplantation for patients with severe combined immunodeficiency (SCID): A PIDTC study.

Journal of human immunity·2026
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

This study extends multiple stepwise test procedures to heteroscedastic settings for identifying the maximum safe dose. These methods are crucial for analyzing toxicological data, improving safety assessments in practice.

Area of Science:

  • Biostatistics
  • Toxicology
  • Statistical Methods

Background:

  • Identifying the maximum safe dose is critical in toxicological studies.
  • Existing multiple stepwise test procedures are limited to homoscedastic data.
  • Toxicological data frequently exhibit heteroscedasticity, necessitating advanced statistical approaches.

Purpose of the Study:

  • To extend existing multiple stepwise test procedures to the heteroscedastic setting.
  • To provide practical tools for identifying the maximum safe dose in the presence of heteroscedasticity.
  • To evaluate the performance of the proposed procedures.

Main Methods:

  • Extension of Tamhane et al.'s multiple stepwise test procedures.
  • Application to heteroscedastic statistical models.

Related Experiment Videos

  • Monte Carlo simulations to assess Type I familywise error rate and power.
  • Illustration using a real-world toxicological data example.

    • Main Results:

    • The proposed extensions effectively handle heteroscedastic toxicological data.
    • Simulations demonstrate favorable Type I error rate control and power properties.
    • The procedures provide a robust method for maximum safe dose determination.

    Conclusions:

    • The developed procedures offer a valuable extension for analyzing heteroscedastic toxicological data.
    • These methods enhance the reliability of maximum safe dose identification in practical applications.
    • The study underscores the importance of accounting for heteroscedasticity in dose-response assessments.